What You Should Know
The Expansion: LinusBio has expanded the availability of its ClearStrand-ASD test to children up to age 10. Previously, the test was only validated for children under 48 months.The Technology: ClearStrand-ASD is a first-of-its-kind biochemical screening test. It requires only a single, noninvasive strand of hair, which can be collected from children as young as one month old.How It Works: In a CLIA-certified laboratory, proprietary robotics and lasers analyze hundreds of
Read More
Life Sciences | News, Analysis, Insights - HIT Consultant
NVIDIA and Persistent Systems Partner to Bring ‘Agentic AI’ to Drug Discovery
What You Should Know
The Partnership: Persistent Systems, a global digital engineering firm, is collaborating with NVIDIA to deploy AI-powered solutions specifically for the Healthcare and Life Sciences (HLS) sector.The Goal: The collaboration aims to move BioPharma companies out of the "AI experimentation" phase and into real-world, production-grade deployments for computational drug discovery and research.The Tech Stack: Persistent is utilizing the full-stack NVIDIA AI platform, including
Read More
HIMSS26: Verily and Samsung Partner to Integrate Galaxy Watch 8 into Precision Health Platform
What You Should Know
The Partnership: Verily Life Sciences and Samsung Electronics America are collaborating to integrate the Samsung Galaxy Watch 8 directly into Verily’s precision health platform, Pre.The Clinical Goal: The joint solution is designed to accelerate research for life sciences and government customers by allowing them to run real-world studies using continuous, consumer-grade wearable data.The Hardware: The Galaxy Watch 8 acts as a robust clinical tool, bringing FDA-cleared
Read More
Why Pharma Must Adopt “Decision Engines” for Medical Engagement
Pharma medical affairs teams have spent the last decade investing heavily in digital transformation. Virtual advisory boards, omnichannel platforms, CRM systems, and analytics dashboards are now standard. Yet despite this progress, many medical engagement strategies still appear static. Plans are often locked in annually, channels are treated as separate silos, and success is measured by activity rather than relevance.
The disconnect is not a lack of data or tools. It is that engagement
Read More
Havas Health and BrightInsight Form Global Digital Health Partnership for Biopharma
What You Should Know
The Alliance: Havas Health has announced an exclusive, strategic partnership with BrightInsight, designating the firm as its single global agency partner for digital persistence and adherence solutions.The Core Problem: The pharmaceutical industry loses an estimated $500 billion annually because patients fail to adhere to or persist with their prescribed therapies.The Technology: BrightInsight brings a pre-vetted, regulatory-compliant digital health platform (powering
Read More
Lessons from COVID-19: How Agile Governance is Transforming Pharmaceutical Launch Readiness
The COVID-19 pandemic forced the pharmaceutical industry to do what once seemed impossible: compress launch cycles that traditionally stretched over a decade into mere months.
The urgency of the crisis redefined what “readiness” meant, with organizations working across functions, geographies, and regulators at a pace previously unthinkable. While the world has shifted into a post-pandemic reality, the lessons learned from this period of radical acceleration remain invaluable. The
Read More
Verily Launches Self-Serve Access to Pre Platform with New Segmed and RefinedScience Datasets
What You Should Know
The Launch: Alphabet's Verily is lowering the barrier to entry for biomedical research by launching a free, self-serve "Standard tier" for its Pre precision health platform.The Tech: Researchers can now instantly access Verily's Exchange (data catalog) and Workbench (trusted research environment) using just a Google account, bypassing months of traditional IT provisioning and data-use red tape.The Data: The launch includes three massive new datasets: an Acute Myeloid
Read More
Sensei Biotherapeutics Acquires Faeth Therapeutics, Raises $200M to Solve PI3K Resistance
What You Should Know
The Deal: Sensei Biotherapeutics has acquired Faeth Therapeutics in a stock-for-stock transaction. Concurrently, Sensei raised a massive $200M in private placement financing to fuel the combined company.The Asset: The centerpiece of the deal is PIKTOR, an oral drug combination that targets the PI3K/AKT/mTOR pathway. Unlike previous drugs that hit just one "node," PIKTOR hits multiple nodes simultaneously to prevent the tumor from finding a workaround.The Promise: In early
Read More
Merck to Leverage Mayo Clinic Platform_Orchestrate for AI-Enabled Drug Discovery
What You Should Know
The Deal: Merck and Mayo Clinic have signed a strategic research agreement to apply AI and multimodal data to drug discovery. This is Mayo Clinic's first collaboration of this scale with a global biopharma company.The Data: Merck gains access to Mayo Clinic Platform_Orchestrate, a treasure trove of de-identified clinical data, genomic datasets, lab results, imaging, and clinical notes from the world's top-ranked hospital system.The Focus: The partnership will initially
Read More
The “Pilot Purgatory”: Why 80% of Pharma AI Projects Fail (And How to Fix It)
Artificial intelligence is rapidly reshaping the life sciences industry, influencing everything from early-stage drug discovery to clinical operations, manufacturing, and patient engagement. While enthusiasm for AI remains strong, many organizations continue to struggle with moving from experimentation to scalable, enterprise-ready deployment. Recent industry data found that 80% of healthcare AI projects fail to scale beyond the pilot phase. In highly regulated environments like healthcare, AI
Read More
